文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于 Y-SPECT/CT 体素剂量测定的 Y 放射性栓塞玻璃微球后肝细胞癌肿瘤剂量反应。

Hepatocellular Carcinoma Tumor Dose Response After Y-radioembolization With Glass Microspheres Using Y-SPECT/CT-Based Voxel Dosimetry.

机构信息

Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):451-461. doi: 10.1016/j.ijrobp.2018.05.062. Epub 2018 Jun 2.


DOI:10.1016/j.ijrobp.2018.05.062
PMID:30191875
Abstract

PURPOSE: To investigate hepatocellular carcinoma tumor dose-response characteristics based on voxel-level absorbed doses (D) and biological effective doses (BED) using quantitative Y-single-photon emission computed tomography (SPECT)/computed tomography (CT) after Y-radioembilization with glass microspheres. We also investigated the relationship between normal liver D and toxicities. METHODS AND MATERIALS: Y-radioembolization activity distributions for 34 patients were based on quantitative Y-bremsstrahlung SPECT/CT. D maps were generated using a local-deposition algorithm. Contrast-enhanced CT or magnetic resonance imaging scans of the liver were registered to Y-SPECT/CT, and all tumors larger than 2.5 cm diameter (53 tumors) were segmented. Tumor mean D and BED (Dmean and BEDmean) and dose volume coverage from 0% to 100% in 10% steps (D0-D100 and BED0-BED100) were extracted. Tumor response was evaluated on follow-up using World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), and modified RECIST (mRECIST) criteria. Differences in dose metrics for responders and nonresponders were assessed using the Mann-Whitney U test. A univariate logistic regression model was used to determine tumor dose metrics that correlated with tumor response. Correlations among tumor size, tumor Dmean, and tumor dose heterogeneity (defined as the coefficient of variation) were assessed. RESULTS: The objective response rates were 14 of 53, 15 of 53, and 30 of 53 for WHO, RECIST, and mRECIST criteria, respectively. WHO and RECIST response statuses did not correlate with D or BED. For mRECIST responders and nonresponders, D and BED were significantly different for Dmean, D20 to D80, BEDmean, and BED0 to BED80. Threshold doses (and the 95% confidence interval) for 50% probability of mRECIST response (D) were 160 Gy (123-196 Gy) for Dmean and 214 Gy (146-280 Gy) for BEDmean. Tumor dose heterogeneity significantly correlated with tumor volume. No statistically significant association between Dmean to normal liver and complications related to bilirubin, albumin, or ascites was observed. CONCLUSIONS: Hepatocellular carcinoma tumor dose-response curves after Y-radioembolization with glass microspheres showed Dmean of 160 Gy and BEDmean of 214 Gy for D with a positive predictive value of ∼70% and a negative predictive value of ∼62%. No complications were observed in our patient cohort for normal liver Dmean less than 44 Gy.

摘要

目的:利用 Y 放射性微球放射性栓塞后定量 Y 单光子发射计算机断层扫描(SPECT)/计算机断层扫描(CT),基于体素水平吸收剂量(D)和生物有效剂量(BED),研究肝细胞癌肿瘤剂量反应特征。我们还研究了正常肝 D 与毒性之间的关系。

方法与材料:34 例患者的 Y 放射性栓塞活性分布基于定量 Y 韧致辐射 SPECT/CT。使用局部沉积算法生成 D 图。将肝脏的增强 CT 或磁共振成像扫描与 Y-SPECT/CT 配准,并对所有大于 2.5cm 直径的肿瘤(53 个肿瘤)进行分割。提取肿瘤平均 D 和 BED(Dmean 和 BEDmean)以及 0%至 100%的 10%步长的剂量体积覆盖率(D0-D100 和 BED0-BED100)。使用世界卫生组织(WHO)、实体瘤反应评估标准(RECIST)和改良 RECIST(mRECIST)标准对随访时的肿瘤反应进行评估。使用 Mann-Whitney U 检验评估应答者和无应答者之间的剂量指标差异。使用单变量逻辑回归模型确定与肿瘤反应相关的肿瘤剂量指标。评估肿瘤大小、肿瘤 Dmean 和肿瘤剂量异质性(定义为变异系数)之间的相关性。

结果:根据 WHO、RECIST 和 mRECIST 标准,客观缓解率分别为 53 例中的 14 例、15 例和 30 例。WHO 和 RECIST 反应状态与 D 或 BED 不相关。对于 mRECIST 应答者和无应答者,Dmean、D20 至 D80、BEDmean 和 BED0 至 BED80 的 D 和 BED 差异有统计学意义。mRECIST 反应概率为 50%(D)的阈值剂量(95%置信区间)分别为 Dmean 为 160Gy(123-196Gy)和 BEDmean 为 214Gy(146-280Gy)。肿瘤剂量异质性与肿瘤体积显著相关。未观察到 Dmean 与胆红素、白蛋白或腹水相关并发症之间存在统计学显著关联。

结论:Y 放射性微球放射性栓塞后肝细胞癌肿瘤剂量反应曲线显示,Dmean 为 160Gy,BEDmean 为 214Gy,D 的阳性预测值约为 70%,阴性预测值约为 62%。我们的患者队列中,正常肝 Dmean 小于 44Gy 时未观察到并发症。

相似文献

[1]
Hepatocellular Carcinoma Tumor Dose Response After Y-radioembolization With Glass Microspheres Using Y-SPECT/CT-Based Voxel Dosimetry.

Int J Radiat Oncol Biol Phys. 2018-6-2

[2]
Quantitative evaluation of Y-PET/CT and Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization.

Med Phys. 2024-9

[3]
Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.

Nucl Med Commun. 2015-4

[4]
Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma.

Int J Radiat Oncol Biol Phys. 2018-2-9

[5]
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.

J Vasc Interv Radiol. 2014-2

[6]
Prediction of Tumor Control in Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.

J Nucl Med. 2019-5-30

[7]
Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.

Eur J Nucl Med Mol Imaging. 2015-10

[8]
Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.

J Vasc Interv Radiol. 2014-10

[9]
Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.

J Nucl Med. 2016-6-15

[10]
Radioembolization of hepatocarcinoma with Y glass microspheres: treatment optimization using the dose-toxicity relationship.

Eur J Nucl Med Mol Imaging. 2020-12

引用本文的文献

[1]
The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC.

Eur J Nucl Med Mol Imaging. 2025-5-22

[2]
Radioembolization of hepatocellular carcinoma with Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability.

Eur J Nucl Med Mol Imaging. 2025-5-21

[3]
Treatments and cancer: implications for radiologists.

Front Immunol. 2025-4-16

[4]
SPECT/CT Dosimetry of Bronchial Artery Tc Macroaggregated Albumin Injection in Pulmonary Malignancies: Feasibility Evaluation of Bronchial Artery Y Radioembolization.

Radiology. 2025-2

[5]
Arterial hypoperfusion as a negative predictive marker for primary hepatic malignancies treated with Y-90 glass microsphere transarterial radioembolization.

Front Oncol. 2024-8-7

[6]
Quantitative evaluation of Y-PET/CT and Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization.

Med Phys. 2024-9

[7]
Y-/Ho- 'Radiation lobectomy' for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics.

JHEP Rep. 2023-12-5

[8]
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.

Eur J Nucl Med Mol Imaging. 2024-3

[9]
AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization.

J Appl Clin Med Phys. 2024-2

[10]
Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma.

Eur J Nucl Med Mol Imaging. 2023-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索